Insulin Production From Transgenic Safflower
Filed in archive Drugs, Vaccines and Therapeutics , Food and Agriculture on July 19, 2006
SemBioSys Genetics Inc. announce success in producing human insulin in transgenic safflower, exceeding its target and achieving accumulation levels of 1.2 percent of total seed protein. The company claims that this breakthrough in plant-produced insulin have the potential to "fundamentally transform the economics and scale of insulin production."
"These results demonstrate that we have produced an authentic insulin molecule in safflower at commercially viable levels. [snip]
At these levels we can produce over one kilogram of insulin per acre of safflower production, which is enough to supply 2,500 patients for one year of treatment. We believe that we could meet the world's total projected insulin demand in 2010 with less than 16,000 acres of crop production.
SemBioSys also claims that its safflower-produced insulin can be up to 40% cheaper than insulin manufactured via current production methods. The firm now plans to scale up production of the diabetes drug and file an Investigational New Drug (IND) application to the FDA in 2007.
More information from SemBioSys' news release.
At these levels we can produce over one kilogram of insulin per acre of safflower production, which is enough to supply 2,500 patients for one year of treatment. We believe that we could meet the world's total projected insulin demand in 2010 with less than 16,000 acres of crop production.
Permalink: Insulin Production From Transgenic Safflower
Tags: insulin diabetes biotech production safflower insulin+production transgenic+safflower food+agricultu
Vote for Insulin Production From Transgenic Safflower:
|
Rating: 6.38 out of 60 vote(s) cast.
|
Response from:
Razique Anwer
(05/18/09 3:29am)
Collip, a professor at the University of Alberta, had experience in the chemistry of hormones. Prior to January 1922, he had prepared an insulin pure enough to be used on human patients. The first patient to receive insulin was 14-year-old Leonard Thompson. Thompson was admitted to Toronto General Hospital with a high blood glucose level; he also was urinating between three and five liters of fluid per day. Despite his rigid diet of only 450 calories (the only known treatment at this time was a diet low in carbohydrates), Thompson continued to excrete (get rid of through bodily waste) large amounts of glucose. On January 11, 1922, he was given insulin. Within a fairly short time, his blood sugar level came down and he stopped urinating large amounts of liquid.
Response from:
rendev
(08/22/09 2:30am)
SemBioSys Genetics Inc., a canadian biotech company, announced in July 2006 to produce a molecule of insulin perfectly authentic and commercially viable from Safflower (Carthamus tinctorius) plants. Insulin is extracted from the seeds of this plant. Insulin production in seeds also offers flexibility in storage and shipment as a raw material, which has the ability to retain its activity upon extraction from stored seed and the benefits also includes cost factor.
Your information is inspiring to me and these things did help to others. Thanks for sharing this!
Your information is inspiring to me and these things did help to others. Thanks for sharing this!
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells